We randomly assigned @ previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab ( at a dose of @ mg per kilogram of body weight every @ weeks and dacarbazine-matched placebo every @ weeks ) or dacarbazine ( at a dose of @ mg per square meter of body-surface area every @ weeks and nivolumab-matched placebo every @ weeks ) .